BRPI0516937A - formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa - Google Patents

formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa

Info

Publication number
BRPI0516937A
BRPI0516937A BRPI0516937-2A BRPI0516937A BRPI0516937A BR PI0516937 A BRPI0516937 A BR PI0516937A BR PI0516937 A BRPI0516937 A BR PI0516937A BR PI0516937 A BRPI0516937 A BR PI0516937A
Authority
BR
Brazil
Prior art keywords
diseases
formulations
alkylphosphocholin
negatively charged
charged particles
Prior art date
Application number
BRPI0516937-2A
Other languages
English (en)
Inventor
Hansjirg Eibl
Susanne Christine Wieland-Berghausen
Jean Steffan
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004050910A external-priority patent/DE102004050910A1/de
Priority claimed from DE102004055284A external-priority patent/DE102004055284A1/de
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BRPI0516937A publication Critical patent/BRPI0516937A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

FORMULAçõES COM ALQUILFOSFOCOLINAS NA UTILIZAçãO DE PARTìCULAS PORTADORAS DE CARGA NEGATIVA. A presente invenção refere-se a novas formulações de medicamentos, que contêm como substâncias ativas alquilfosfolinas e análogos, alquil-alcanodiol-fosfocolinas e análogos, bem como (éter)-lisolecitinas e análogos em diversas formas de realização. Neste caso, as substâncias ativas são componentes integrais de lipossomas, que além disso, contêm colesterol e análogos, bem como um portador de carga negativo. As formulações de medicamentos são particularmente adequadas para o tratamento ou/e profilaxia de câncer, de doenças provocadas por protozoários, tais como leishmanioses e doenças provocadas por amebas, de ascaridíase e de doenças, que são provocadas por artrópodes, bem como doenças bacterianas, tais como por exemplo, erliquiose. Também doenças dos olhos, que são acompanhadas por processos celulares descontrolados, podem ser influenciadas favoravelmente.
BRPI0516937-2A 2004-10-19 2005-10-19 formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa BRPI0516937A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004050910A DE102004050910A1 (de) 2004-10-19 2004-10-19 Formulierungen mit Alkylphosphocholinen unter Verwendung von neuen negativen Ladungsträgern
DE102004055284A DE102004055284A1 (de) 2004-11-16 2004-11-16 Formulierungen mit Alkylphosphocholinen unter Verwendung von neuen negativen Ladungsträgern
PCT/EP2005/011252 WO2006042751A2 (de) 2004-10-19 2005-10-19 Formulierungen mit alkylphosphocholinen unter verwendung von neuen negativen ladungsträgern

Publications (1)

Publication Number Publication Date
BRPI0516937A true BRPI0516937A (pt) 2008-09-23

Family

ID=36203318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516937-2A BRPI0516937A (pt) 2004-10-19 2005-10-19 formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa

Country Status (12)

Country Link
US (1) US8828972B2 (pt)
EP (1) EP1827379B8 (pt)
JP (1) JP2008517023A (pt)
KR (1) KR101311980B1 (pt)
AT (1) ATE491437T1 (pt)
BR (1) BRPI0516937A (pt)
CA (1) CA2584537C (pt)
CY (1) CY1111335T1 (pt)
DE (1) DE502005010699D1 (pt)
DK (1) DK1827379T3 (pt)
PT (1) PT1827379E (pt)
WO (1) WO2006042751A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
JP5623076B2 (ja) * 2007-07-20 2014-11-12 株式会社コーセー ベシクル組成物、及び皮膚外用剤
DE102009007853A1 (de) * 2009-02-06 2010-08-12 LMU Ludwig-Maximilians-Universität München Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe
ES2350075B1 (es) * 2009-05-11 2011-11-10 Maria Pilar Mateo Herrero Composicion microencapsulada a base de olea europaea saponificada, suuso y su procedimiento de obtencion.
CA2818194A1 (en) 2010-11-22 2012-05-31 Dafra Pharma Research&Development Bvba Solid dosage forms of oleyl phosphocholine
CN105326824A (zh) * 2015-11-06 2016-02-17 暨南大学 棕榈酸在制备杀灭水产动物体外寄生虫药物中的应用
KR102330620B1 (ko) 2020-05-18 2021-11-23 한림대학교 산학협력단 옴진드기 감염의 진단 및 치료 모니터링을 위한 정보 제공 방법
KR102807388B1 (ko) 2022-03-03 2025-05-14 한림대학교 산학협력단 핵산 기반의 측면 흐름 분석을 이용한 옴진드기의 감염 진단용 정보 제공 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4615885A (en) * 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3872875T2 (de) * 1987-02-27 1993-02-25 Terumo Corp Verfahren zur herstellung von liposomen.
JPH01180245A (ja) * 1988-01-12 1989-07-18 Terumo Corp リポソーム
DE4132345A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
DE4308121A1 (de) * 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
KR100381449B1 (ko) 1994-10-14 2003-07-18 더 리포좀 컴퍼니, 인코퍼레이티드 에테르지질리포좀과이들의제약학적용도
US5711964A (en) * 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5932242A (en) 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
PT1135193E (pt) 1998-12-04 2003-01-31 Max Delbrueck Centrum Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
GB9918670D0 (en) * 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10148067A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
DE10242367A1 (de) * 2002-09-12 2004-03-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Thermolabiles Liposom mit geregelter Freigabetemperatur

Also Published As

Publication number Publication date
US8828972B2 (en) 2014-09-09
US20080090781A1 (en) 2008-04-17
CA2584537C (en) 2013-09-24
DK1827379T3 (da) 2011-04-04
DE502005010699D1 (de) 2011-01-27
PT1827379E (pt) 2011-03-23
WO2006042751A2 (de) 2006-04-27
ATE491437T1 (de) 2011-01-15
CA2584537A1 (en) 2006-04-27
KR101311980B1 (ko) 2013-09-26
JP2008517023A (ja) 2008-05-22
EP1827379B1 (de) 2010-12-15
CY1111335T1 (el) 2015-08-05
EP1827379A2 (de) 2007-09-05
EP1827379B8 (de) 2011-05-25
KR20070074626A (ko) 2007-07-12
WO2006042751A3 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
CY1111335T1 (el) Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
SE0202539D0 (sv) Compounds
MA29480B1 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
SG10201407996PA (en) Lipids, lipid compositions, and methods of using them
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MY143795A (en) Tetrahydropyridoindole derivatives
TNSN07005A1 (fr) Analogues tetrapeptidiques
WO2008075376A8 (en) Polymorphic forms of bortezomib and process for their preparation
TW200833670A (en) Novel compounds 569
EA201300908A1 (ru) ПРОИЗВОДНЫЕ 6-ЦИКЛОБУТИЛ-1,5-ДИГИДРОПИРАЗОЛО[3,4d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE9A
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
PE20130640A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie
FR2968662B1 (fr) Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
ATE549923T1 (de) Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.